HBO1 suppresses anti-tumor immunity of CD8⁺ T Cells in thyroid cancer by recruiting BRD4 to regulate VTCN1 expression
Cancer Immunology, Immunotherapy · 2026
DOI: 10.1007/s00262-026-04491-z ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Yan Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The Affiliated Cancer Hospital of Xiangya School of Medicine Central, South University/Hunan Cancer Hospital, Changsh…. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Thyroid Neoplasms, Transcription Factors, Cell Cycle Proteins. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Hunan Provincial Natural Science Foundation, the National Natural Sciences Foundation of China, the High-Level Talent Support Program of Hunan Cancer Hospital.
Abstract (Originalsprache)
Thyroid cancer is the most common endocrine malignancy. Although surgery remains the primary treatment, advanced disease frequently recurs or metastasizes, and subsequent therapies yield suboptimal outcomes. Immunotherapy holds promise, yet the underlying immune-evasion mechanisms remain incompletely understood. HBO1, a multifunctional acyltransferase, plays a significant role in tumor immune regulation. Our previous research revealed that HBO1 is highly expressed in thyroid cancer tissues, promotes malignant progression, and inhibits CD8+ T cell function. To further elucidate the role and mechanism of HBO1 in thyroid cancer immune regulation, we conducted the following investigations. Firstly, using an in vitro co-culture model analyzed by flow cytometry and ELISA assays, we found that HBO1 overexpression induces CD8+ T cell apoptosis and significantly suppresses their cytotoxic function and secretion of effector molecules. Secondly, leveraging bioinformatic analysis of CUT&Tag datasets combined with in vitro cellular experiments, we found that HBO1 was associated with increased VTCN1 expression in an H3K14 acetylation-dependent manner, thereby contributing to CD8+ T cell dysfunction. Subsequently, employing RNA-seq analysis, ChIP-qPCR, dual-luciferase reporter assays, co-immunoprecipitation (Co-IP), and in vivo experiments, we further explored the underlying mechanism and found that HBO1 may facilitate BRD4 enrichment at the VTCN1 promoter through H3K14 acetylation, thereby promoting VTCN1 transcription and contributing to anti-tumor immune suppression in thyroid cancer. Finally, through IP-MS and Co-IP experiments, we identified the E3 ligase TRIM21 as a potential upstream regulator of HBO1. TRIM21 modulates HBO1 acetyltransferase activity by promoting its ubiquitination-mediated degradation, consequently influencing HBO1-associated immune escape in thyroid cancer. In summary, this study suggests that HBO1 may regulate VTCN1 expression through an H3K14ac-BRD4-associated mechanism in thyroid cancer, thereby contributing to suppression of CD8+ T cell anti-tumor immunity. In addition, TRIM21 may participate in the regulation of HBO1 protein stability and its associated immune-related signaling. Our findings provide new experimental evidence for understanding immune escape mechanisms and exploring potential immunotherapeutic targets in thyroid cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, The Affiliated Cancer Hospital of Xiangya School of Medicine Central, South University/Hunan Cancer Hospital, Changsha, 410013, Hunan, China.
- Cancer Research Institute, Basic School of Medicine, Central South University, Changsha, 410011, Hunan, China.
- Department of Pathology, The Third Xiangya Hospital of Central South University,, Changsha, 410013, Hunan, China.
- Department of Blood Transfusion, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, 410013, Hunan, China.
- Department of Radiation Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, 410013, Hunan, China.
- Cancer Research Institute, Basic School of Medicine, Central South University, Changsha, 410011, Hunan, China. zhouyanhong@csu.edu.cn.
Förderung
- Hunan Provincial Natural Science Foundation
- the National Natural Sciences Foundation of China
- the High-Level Talent Support Program of Hunan Cancer Hospital
- Health Commission of Hunan Province Research Project
Zitieren
APA
Chen, Y., Zeng, F., Liao, S., Lei, Y., He, Q., Zhou, Y., Li, Y., & Long, C. (2026). HBO1 suppresses anti-tumor immunity of CD8⁺ T Cells in thyroid cancer by recruiting BRD4 to regulate VTCN1 expression. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04491-z
Vancouver
Chen Y, Zeng F, Liao S, Lei Y, He Q, Zhou Y, et al. HBO1 suppresses anti-tumor immunity of CD8⁺ T Cells in thyroid cancer by recruiting BRD4 to regulate VTCN1 expression. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04491-z
BibTeX
@article{Chen2026,
author = {Chen, Yan and Zeng, Feng and Liao, Shan and Lei, Yan and He, Qian and Zhou, Yanhong and Li, Yanling and Long, Chen},
title = {HBO1 suppresses anti-tumor immunity of CD8⁺ T Cells in thyroid cancer by recruiting BRD4 to regulate VTCN1 expression},
journal = {Cancer Immunology, Immunotherapy},
year = {2026},
doi = {10.1007/s00262-026-04491-z}
}
EUVIMED